Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Raman Active, Smart Diatom Frustules as Next Generation Multimodal Theranostics for Safe and Superior Colorectal Cancer Treatment

Descripción del proyecto

Nanoteranóstica inteligente contra el cáncer colorrectal

Los tratamientos actuales para el cáncer colorrectal, como la quimioterapia, la radioterapia y la cirugía, son inespecíficos y provocan efectos secundarios importantes. Esto pone de manifiesto la urgente necesidad de estrategias más seguras y eficaces. El equipo del proyecto DIASHUTTLE, que cuenta con el apoyo de las Acciones Marie Skłodowska-Curie, pretende desarrollar una plataforma nanoteranóstica multifuncional que combine nanopartículas magnéticas y de oro, ácido fólico dirigido contra tumores y el compuesto natural astaxantina. Este novedoso método pretende lograr simultáneamente la administración selectiva de fármacos, la hipertermia magnética y el tratamiento fototérmico. También facilitará el seguimiento instantáneo mediante obtención de imágenes y espectroscopia. DIASHUTTLE promete una mayor eficacia anticancerígena y una toxicidad reducida.

Objetivo

Colorectal cancer accounted for 12.7% of all new cancer diagnosis and 12.4% of all deaths due to cancer in European Union in 2020. Despite the advances in therapeutics, it is the most recurrent tumors in humans and third common cause of cancer-related deaths worldwide. The current treatment options include chemotherapy, radiation and surgery that are invasive and have side-effects. Also, the 1st and 2nd generation nanocarriers used in cancer therapy consisted of mono-component systems and failed due to lack of targeting molecules, remotely controlled therapeutics window, and patient-specific individualized platforms. The project DIASHUTTLE aims to develop a novel, next-generation, smart, multifunctional and multimodal, hybrid nanotheranostic platform consisting of biosilica extracted from living diatoms for simultaneous diagnosis, treatment, and therapy monitoring of colorectal cancer. It will combine magnetic nanoparticle core, surface deposited metallic gold nanoparticles, tumor targeting biomolecule folic acid, and natural source drug astaxanthin to facilitate different modes of therapy such as magnetically guided or ligand targeted drug delivery, magnetic hyperthermia, and photothermal therapy. It will also concurrently enable different modes of real-time monitoring such as Raman, surface enhanced Raman spectroscopy, magnetic resonance imaging, fluorescence, and photoluminescence. It is expected that the combination of different therapies will exhibit superior synergistic anti-cancer effect over monotherapy and reduce treatment delays by offering a safe and personalized approach to overcome the limitations of conventional cancer treatment. The proposed platform will lead to less toxicity due to the use of targeting molecule and natural materials, controlled drug release, and lower effective drug concentration. Additionally, the nutrient uptake and CO2 sequestration capability of diatoms will support circular bio-economy and self-sustainability.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-MSCA-2022-PF-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

CONSIGLIO NAZIONALE DELLE RICERCHE
Aportación neta de la UEn
€ 235 737,60
Coste total
Sin datos

Socios (1)